

5-14-2020

## **Covid-19 Clinical Update 5/14/2020**

George Washington University

Follow this and additional works at: <https://hsrc.himmelfarb.gwu.edu/infectiousdiseaseupdates>

---

### **Recommended Citation**

George Washington University, "Covid-19 Clinical Update 5/14/2020" (2020). *GW Infectious Disease Updates*. Paper 10.

<https://hsrc.himmelfarb.gwu.edu/infectiousdiseaseupdates/10>

This Presentation is brought to you for free and open access by the GW Covid-19 Collection at Health Sciences Research Commons. It has been accepted for inclusion in GW Infectious Disease Updates by an authorized administrator of Health Sciences Research Commons. For more information, please contact [hsrc@gwu.edu](mailto:hsrc@gwu.edu).



1. EPIDEMIOLOGY

2. PATHOPHYSIOLOGY

4. TREATMENT

5. GW UPDATES

# COVID-19 UPDATE

HANA AKSELROD, MD, MPH

GW DIVISION OF INFECTIOUS DISEASES

5/14/2020

# Disclosures

- No financial COI
- Some pre-print/investigational information discussed




## BENEFITS OF JUST SAYING "A PDF":

- AVOIDS IMPLICATIONS ABOUT PUBLICATION STATUS
- IMMEDIATELY RAISES QUESTIONS ABOUT AUTHOR(S)
- STILL IMPLIES "THIS DOCUMENT WAS PROBABLY PREPARED BY A PROFESSIONAL, BECAUSE NO NORMAL HUMAN TRYING TO COMMUNICATE IN 2020 WOULD CHOOSE THIS RIDICULOUS FORMAT."


There are a total of **3,179 deaths** and **70,452 cases** confirmed in the region.




By **Rebecca Tan, Fenit Nirappil, Kevin Uhrmacher, Gabriel Florit and Danielle Rindler**  
Updated May 14 at 10:50 a.m.



### New daily cases reported in D.C., Maryland and Virginia



### New daily deaths reported in D.C., Maryland and Virginia






# Spike mutation pipeline reveals the emergence of a more transmissible form of SARS-CoV-2

[ID](#) B Korber, [ID](#) WM Fischer, [ID](#) S Gnanakaran, H Yoon, [ID](#) J Theiler, W Abfalterer, [ID](#) B Foley, EE Giorgi, [ID](#) T Bhattacharya, MD Parker, DG Partridge, CM Evans, TM Freeman, [ID](#) TI de Silva, on behalf of the Sheffield COVID-19 Genomics Group, [ID](#) CC LaBranche, [ID](#) DC Montefiori

doi: <https://doi.org/10.1101/2020.04.29.069054>

This article is a preprint and has not been certified by peer review [what does this mean?].



**Fig. 2. The proportion of sequences carrying the D614G mutation is increasing in every region that was well sampled in the GISAID database through the month of March. A) A table**

**Fig. 3. Running weekly average counts showing the relative amount of D614 (orange) and G614, (blue) in different regions of the world. In almost every case soon after G614 enters a region, it begins to dominate the sample. Fig. S3 shows the same data, illustrated as a daily cumulative plot. Plots were generated with Python Matplotlib (Hunter, 2007). The plots shown here and in Fig. S3 can be recreated with contemporary data from GISAID at [www.cov.lanl.gov](http://www.cov.lanl.gov).**


# An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Lucio Verdoni, MD • Angelo Mazza, MD • Annalisa Gervasoni, MD • Laura Martelli, MD • Maurizio Ruggeri, MD •

Matteo Ciuffreda, MD • et al. [Show all authors](#)

Published: May 13, 2020 • DOI: [https://doi.org/10.1016/S0140-6736\(20\)31103-X](https://doi.org/10.1016/S0140-6736(20)31103-X)  Check for updates

**Interpretation** In the past month we found a 30-fold increased incidence of Kawasaki-like disease. Children diagnosed after the SARS-CoV-2 epidemic began showed evidence of immune response to the virus, were older, had a higher rate of cardiac involvement, and features of MAS. The SARS-CoV-2 epidemic was associated with high incidence of a severe form of Kawasaki disease. A similar outbreak of Kawasaki-like disease is expected in countries involved in the SARS-CoV-2 epidemic.



## Kawasaki-like disease: emerging complication during the COVID-19 pandemic



Children have to date borne a minimal medical burden in the global COVID-19 pandemic. Epidemiological data from many countries show that children are a small minority of those who test positive. Children younger than 18 years have made up only 1.7% of national cases in the USA,<sup>1</sup> 1% of cases in the Netherlands,<sup>2</sup> and 2.0% of a large observational cohort in the UK.<sup>3</sup> Whether these proportions reflect lower susceptibility among children versus adults,<sup>4</sup> or similar infection rates, but much higher proportions with asymptomatic disease, is unclear.<sup>5</sup> Studies from several countries have confirmed that severe illness and death due to COVID-19 among children are rare,<sup>1,6</sup> with accurate estimates unavailable because of an absence of true population denominators.

with hypotension requiring fluid resuscitation, and two of ten children needing inotropic support. Two of ten children had a positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) PCR swab and eight of ten had a SARS-CoV-2-positive serology test; however, these tests were not done contemporaneously with the episode, so the clinical relevance is unclear. The majority of patients with Kawasaki disease respond well to intravenous immunoglobulin; however, 10–20% require additional anti-inflammatory treatment.<sup>9</sup> In this cohort, eight of ten children received high-dose corticosteroids in addition to intravenous immunoglobulin. These differences raise the question as to whether this cluster is Kawasaki disease with SARS-CoV-2 as the triggering



Published Online  
May 13, 2020  
[https://doi.org/10.1016/S0140-6736\(20\)31129-6](https://doi.org/10.1016/S0140-6736(20)31129-6)  
See Online/Articles  
[https://doi.org/10.1016/S0140-6736\(20\)31103-X](https://doi.org/10.1016/S0140-6736(20)31103-X)

## Rare, Severe COVID-19-Associated Illness Reported In UK and US Children; Virtual World Health Assembly Scheduled For 18–19 May

Pandemics & Emergencies 06/05/2020 • Grace Ren & Elaine Ruth Fletcher



# GW Updates



- University Virtual Graduation on Sunday
- Hospital census
- LabCorp SARS-CoV-2 IgM and IgG tests
- Funding opportunities
- Therapeutic trials coming in, targeting severe inflammation cascade
- Convalescent plasma under Mayo/Red Cross protocol, supply limited
- ID working on remdesivir access, supply likely to also be limited

